Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer - a Randomized, Phase 2 Study

NCT05816655 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05816655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05816655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer - a Randomized, Phase 2 Study
Lead sponsor
Korea University Guro Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 31, 2023
Completion date
June 30, 2029
Enrollment
202 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer